InMed Pharmaceuticals Inc. plans to wind down BayMedica LLC's commercial operations due to negative impacts from legislative changes effective November 12, 2026. The company expects to incur costs of around $670,000 and will transition to focusing on developing its drug candidates, INM-901 and INM-089, in the coming fiscal year.